Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBT: 2020-2025

Historic EBT for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' EBT rose 40.96% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.2 million, marking a year-over-year increase of 18.84%. This contributed to the annual value of -$44.5 million for FY2024, which is 16.53% up from last year.
  • Per Silence Therapeutics' latest filing, its EBT stood at -$21.0 million for Q3 2025, which was up 23.36% from -$27.3 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' EBT registered a high of $12.6 million during Q4 2024, and its lowest value of -$35.5 million during Q3 2024.
  • Moreover, its 3-year median value for EBT was -$18.6 million (2023), whereas its average is -$16.7 million.
  • Its EBT has fluctuated over the past 5 years, first soared by 167.97% in 2024, then crashed by 1,279.59% in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' EBT stood at -$15.1 million in 2021, then fell by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then soared by 167.97% to $12.6 million in 2024, then tumbled by 265.98% to -$21.0 million in 2025.
  • Its last three reported values are -$21.0 million in Q3 2025, -$27.3 million for Q2 2025, and -$28.5 million during Q1 2025.